Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline Intelligence, 2019_Sample Page

1. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019

2. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Introduction CmaxInsight’s, “Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this Indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Cognitive Impairment Associated with Schizophrenia (CIAS). Highlights and Scope of the Report Establish a comprehensive understanding of key competitor information, analysis, and insights to improve R&D strategies Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Discover in-licensing and out-licensing strategies by identifying potential partners with progressing projects for Cognitive Impairment Associated with Schizophrenia (CIAS) to enhance and expand business potential and scope Plan mergers and acquisitions successfully by identifying major players with the most promising pipeline therapeutics in the target demographic Our extensive in-depth analysis on therapy portfolio support the client in decision- making process regarding their therapeutic portfolio by identifying the reason behind the dormant or discontinued drugs Develop strategic initiatives by understanding the focus areas of leading companies Assess challenges and opportunities that influence Cognitive Impairment Associated with Schizophrenia (CIAS) R&D Secondary resources such as Company Websites, Annual Reports, Financial Reports, Analyst Reports, Investor Presentations, Press Releases, web-casts Industry Trade Journals, Pubmed, NCBI, Oxford and other literature and in-house analysis by CmaxInsight’s team of industry experts are referred for preparing the report. Please note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated mechanism of action. 2 ©CmaxInsight|This report is a licensed product and is not to be photocopied

3. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Insights Pipeline Drugs Therapeutic Assessment Disease Overview Insights Leading Company Analysis Clinical Trial Landscape Mergers, Acquisitions & Collaboration Deals 3 ©CmaxInsight|This report is a licensed product and is not to be photocopied

4. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Executive Summary Snapshot Cognitive Impairment Associated with Schizophrenia (CIAS) Snapshot Pipeline at a Glance Phase I Phase III Phase II Pre-Clinical & Discovery Leading Companies & their Most Prominent Targets •Target •Target Company 1 Company 2 Company 3 Company 4 •Target •Target Market Drivers Market Barriers 4 ©CmaxInsight|This report is a licensed product and is not to be photocopied

5. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Table of Contents Introduction ..................................................................................................................... 1 Insights ............................................................................................................................ 3 Executive Summary Snapshot ........................................................................................... 4 Disease Overview ............................................................................................................. 8 Causes .................................................................................................................................... 8 Symptoms .............................................................................................................................. 8 Pathophysiology ..................................................................................................................... 8 Diagnosis ................................................................................................................................ 8 Treatment .............................................................................................................................. 8 Epidemiology.......................................................................................................................... 8 Competitive Landscape ..................................................................................................... 9 Comparative Analysis ............................................................................................................. 9 Pipeline Therapeutics ...................................................................................................... 10 Mid Stage Products (Phase II) .......................................................................................... 11 Comparative Analysis ........................................................................................................... 11 BIIB104: Biogen ............................................................................................................... 12 Description ........................................................................................................................... 12 Product Profile ..................................................................................................................... 12 Research and Development ................................................................................................. 13 Clinical Trial Landscape ........................................................................................................ 13 Product Development Activities .......................................................................................... 15 Early Stage Products (Phase I) .......................................................................................... 16 Comparative Analysis ........................................................................................................... 16 Drug name: Company name ............................................................................................ 17 Product Description ............................................................................................................. 17 Research and Development ................................................................................................. 17 Product Development Activities .......................................................................................... 17 Key Development Milestone ............................................................................................... 17 Pre-clinical and Discovery Products .................................................................................. 19 Comparative Analysis ........................................................................................................... 19 Drug name: Company name ............................................................................................ 20 Product Description ............................................................................................................. 20 Research and Development ................................................................................................. 20 Product Development Activities .......................................................................................... 20 Key Development Milestone ............................................................................................... 20 Featured Clinical Evidence for CIAS .................................................................................. 22 Universities working on Cognitive Impairment Associated with Schizophrenia (CIAS) ....... 23 Patient Support and Advocacy Resources ........................................................................ 24 Therapeutic Assessment .................................................................................................. 25 Assessment by Route of Administration.............................................................................. 25 Assessment by Stage and Route of Administration ............................................................. 26 Assessment by Molecule Type ............................................................................................. 27 Assessment by Stage and Molecule Type ............................................................................ 28 Assessment by Target .......................................................................................................... 29 Assessment by Stage and Target ......................................................................................... 30 5 ©CmaxInsight|This report is a licensed product and is not to be photocopied

6. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Dormant and Discontinued Products ............................................................................... 31 Comparative Analysis ........................................................................................................... 31 Drug name: Company name ............................................................................................ 32 Product Description ............................................................................................................. 32 Research and Development ................................................................................................. 32 Product Development Activities .......................................................................................... 32 Reason for Dormancy / Discontinuation ............................................................................. 32 Leading Companies Analysis ............................................................................................ 33 Biogen Inc.: Company Description ....................................................................................... 33 Company, Total Revenue ..................................................................................................... 34 Revenue by Business Segments ........................................................................................... 34 Geography-Wise Revenue ................................................................................................... 35 Glossary .......................................................................................................................... 36 Price ................................................................................................................................ 37 About CmaxInsight .......................................................................................................... 37 Contact Us ....................................................................................................................... 37 Disclaimer ....................................................................................................................... 37 6 ©CmaxInsight|This report is a licensed product and is not to be photocopied

7. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 List of Tables Table 1: Total Products for Cognitive Impairment Associated With Schizophrenia (CIAS) ....... 9 Table 2: Mid Stage Products (Phase II) .................................................................................... 11 Table 3: Early Stage Products (Phase I) .................................................................................... 16 Table 4: Pre-clinical and Discovery Stage Products ................................................................. 19 Table 5: List of featured Clinical Evidence for Cognitive Impairment Associated with Schizophrenia (CIAS) ................................................................................................................ 22 Table 6: List of Universities working on Cognitive Impairment Associated With Schizophrenia (CIAS) ........................................................................................................................................ 23 Table 7: List of Patient Support and Advocacy Resources ....................................................... 24 Table 8: Assessment by Route of Administration .................................................................... 25 Table 9: Assessment by Stage and Route of Administration ................................................... 26 Table 10: Assessment by Molecule Type ................................................................................. 27 Table 11: Assessment by Stage and Molecule Type ................................................................ 28 Table 12: Assessment by Target .............................................................................................. 29 Table 13: Assessment by Stage and Target ............................................................................. 30 Table 14: Dormant Products .................................................................................................... 31 Table 15: Discontinued Products ............................................................................................. 31 Table 16: Company Profile, 2018 ............................................................................................. 33 List of Figures Figure 1: Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS) .................................................................................................................. 9 Figure 2: Mid Stage Products (Phase II) ................................................................................... 11 Figure 3: Early Stage Products (Phase I) .................................................................................. 16 Figure 4: Assessment by Route of Administration .................................................................. 25 Figure 5: Assessment by Stage and Route of Administration .................................................. 26 Figure 6: Assessment by Molecule Type .................................................................................. 27 Figure 7: Assessment by Stage and Molecule Type ................................................................. 28 Figure 8: Assessment by Target ............................................................................................... 29 Figure 9: Assessment by Stage and Target .............................................................................. 30 Figure 10: Dormant and Discontinued Products ..................................................................... 31 Figure 11: Company, Total Revenue ........................................................................................ 34 Figure 13: Company, Revenue by Business Segments............................................................. 34 Figure 13: Company, Geography-Wise Revenue ..................................................................... 35 7 ©CmaxInsight|This report is a licensed product and is not to be photocopied

8. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Disease Overview Schizophrenia is a major psychiatric disorder characterized by a disruption in affective, cognitive and social domains. Schizophrenia is often accompanied by gross and progressive impairment in different functional areas of a person. They are mostly seen in the form of cognitive impairment (executive functions, information processing & attention, learning and memory), psychomotor activity and speech, thought process, perception, and abstraction. It has a negative impact on patients’ quality of life and ability to function. Causes XXXXX Symptoms Xxxxxx Pathophysiology Xxxx Diagnosis Xxxx Treatment Xxxx Unmet Needs Xxxx Epidemiology Worldwide there are greater than 20 million people living with schizophrenia and it is estimated that the majority of them live with some degree of cognitive impairment attributable to the disease. 8 ©CmaxInsight|This report is a licensed product and is not to be photocopied

9. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Competitive Landscape Comparative Analysis Figure 1: Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS) 10 9 Filed Number of Products 8 Phase III Phase II 6 5 Phase I Pre-Clinical 4 3 3 Discovery 2 2 2 Dormant 2 1 Discontinued 0 Stage of Development Source: CmaxInsight Table 1: Total Products for Cognitive Impairment Associated With Schizophrenia (CIAS) Stage of Development Filed Phase III Phase II Phase I Pre-Clinical Discovery Dormant Discontinued Number of Products Source: CmaxInsight 9 ©CmaxInsight|This report is a licensed product and is not to be photocopied

10. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Pipeline Therapeutics 1 Avadel Pharmaceuticals 1 Arena Pharmaceuticals 1 Filed Balance Therapeutics 1 Phase III Evotec AG Phase II 1 GlaxoSmithKline Phase I 1 Heptares Therapeutics Pre-clinical 1 2 1 Jazz Pharmaceuticals Discovery 1 1 Johnson & Johnson Dormant 1 NLS Pharma Discontinued Company Name 1 Ono Pharmaceutical 1 OptiNose 1 Pfizer 1 Reset Therapeutics 1 Roche 1 Sanofi 1 Seelos Therapeutics 1 Suven Life Sciences 1 Taisho Pharmaceutical 1 Takeda 1 Theranexus 0 1 2 3 4 5 Number of Products 10 ©CmaxInsight|This report is a licensed product and is not to be photocopied

11. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Mid Stage Products (Phase II) Comparative Analysis Figure 2: Mid Stage Products (Phase II) 10 Total Active Products 9 8 Number of Products 6 Phase II Products 2 4 2 0 Stage of Development Source: CmaxInsight Table 2:Mid Stage Products (Phase II) Drug name Company Phase MoA RoA Molecule type Source: CmaxInsight 11 ©CmaxInsight|This report is a licensed product and is not to be photocopied

12. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 BIIB104: Biogen BIIB 104 (previously known as PF 4958242), a small molecule AMPA (a-amino-3-hydroxy-5- methylisoxazole-4-propionic acid) positive allosteric modulator (PAM), is being developed by Biogen, for the oral treatment of CIAS. It was also under development for the treatment of age-related sensorineural hearing loss, but development for this indication was terminated due to insufficient effectiveness. Description Product Description Drug Name BIIB104 Generic Name NA Alias Name PF-04958242, PF-4958242 N-[(3S,4S)-4-[4-(5-cyanothiophen-2- yl)phenoxy]oxolan-3-yl]propane-2-sulfonamide Chemical Name Chemical Formula C18H20N2O4S2 Molecular Weight 392.488 g/mol CAS Registration No. 1258963-59-5 Source: CmaxInsight Product Profile Product Profile Drug Name BIIB104 Biogen (Previously Pfizer; Biogen acquired the product from Pfizer) Mono Company Product Type Therapy Area Neuropsychiatry Cognitive Impairment Associated with Schizophrenia (CIAS) Indications Highest Stage of Development Phase IIb Designation NA Route of Administration Oral Formulation Capsule Target Mechanism of Action AMPA receptor AMPA receptor Potentiator Technology NA Molecule Type Small Molecule Drug Origin Synthetic Source Source: CmaxInsight 12 ©CmaxInsight|This report is a licensed product and is not to be photocopied

13. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Research and Development Clinical Studies Clinical Trials Description Intervention (Sponsor) NCT No. Start date 1 ⁰ Phase Status Indication Completion II Recruiting BIIB104 (Biogen) CIAS NCT03745820 Nov 2018 Apr 2020 II Terminated PF-04958242 (Pfizer) CIAS NCT02855411 Aug 2016 Sep 2016 I Completed PF-04958242 (Pfizer) Ketamine Induced Cognitive Impairment In Healthy Male Volunteers NCT01749098 Dec 2012 Feb 2014 Source: CmaxInsight Clinical Trial Landscape NCT03745820 (Recruiting): Study Design & Details Phase Sponsor Biogen II Start date Nov 2018 Study Design 1⁰ Completion Apr 2020 Randomized, Double-Blind, Multiple-Dose, Placebo- Controlled Study Adult (18-50 years) with CIAS N=219 Subjects must be in ongoing maintenance atypical antipsychotic therapy (except clozapine) BIIB 104 0.5mg or 0.15mg BID orally for 12 week Placebo Primary: MCCB Working Memory Domain Score at Week 12 Secondary: Adverse Events (AEs) and Serious Adverse Events (SAEs) up to Week 14 Change from Baseline in UPSA-B, SCoRS Assessment, MCCB Composite and Individual Domain Scores, PANSS Total Score and Subscale Scores, CGI-S at Week 12 CGI-I at Week 12 United States Trial ID NCT03745820 Population Prior Rx Study Drug/Regimen Comparator/Regimen Endpoints: Location Source: CmaxInsight 13 ©CmaxInsight|This report is a licensed product and is not to be photocopied

14. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 NCT02855411(Terminated): Study Design & Details Phase Sponsor Pfizer II Start date Aug 2016 Study Design 1⁰ Completion Sep 2016 Randomized, Double-blind, Placebo Controlled, Parallel Group Study Adult (18-50 years) with CIAS N=35 Subjects must be in ongoing maintenance atypical antipsychotic therapy (except clozapine) PF-04958242 0.5mg or 0.15mg BID orally for 12 week Placebo Primary: Change From Baseline in the MCCB Working Memory Domain and UPSA‑VIM at Baseline, Week 2, Week 6, Week 12 Trial ID NCT02855411 Population Prior Rx Study Drug/Regimen Comparator/Regimen Endpoints: Reason for Termination Reason The trial is terminated prematurely on September 22, 2016 following an internal portfolio prioritization. It is not due to any safety concern or change in benefit: risk assessment.) NCT02855411 Source Source: CmaxInsight NCT01749098 (Completed): Study Design & Details Phase Sponsor Pfizer Ib Start date Dec 2012 Study Design 1⁰ CompletionFeb 2014 Randomized, Subject And Investigator Blinded, Sponsor Open Placebo Controlled, 2 Way, Crossover Study Ketamine Induced Cognitive Impairment in Healthy Male Volunteers (21- 45 years) NA PF-04958242 0.35 mg orally administered capsule on Day 1 and 0.25 mg orally administered capsule on Days 2-5 Placebo Primary: Test score on the Hopkins Verbal Learning Test - Immediate Recall at Day 5 Secondary: Test score on the Weschler Digit Span Test, CogState N-back test, CogState Spatial Working memory test, CogState One Card Learning test, Hopkins Verbal Learning test, and Positive and Negative Syndrome Scale at Day 5 Trial ID NCT01749098 Population Prior Rx Study Drug/Regimen Comparator/Regimen Endpoints: Results Safety PF-04958242 demonstrated an acceptable safety profile and treatment effect trends across multiple domains of cognition in Phase Ib clinical studies Biogen PR Source Source: CmaxInsight 14 ©CmaxInsight|This report is a licensed product and is not to be photocopied

15. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Product Development Activities Acquisition 12 March, 2018: Biogen announced an agreement to acquire PF-04958242 from Pfizer. The purchase includes an upfront payment of $75 million with up to $515 million in additional development and commercialization milestone payments, as well as tiered royalties in the low to mid-teen percentages. 15 ©CmaxInsight|This report is a licensed product and is not to be photocopied

16. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Early Stage Products (Phase I) Comparative Analysis Figure 3: Early Stage Products (Phase I) 10 Total Active Products 9 8 Number of Products 6 Phase I Products 2 4 2 0 Stage of Development Source: CmaxInsight Table 3:Early Stage Products (Phase I) Drug name Company Phase MoA RoA Molecule type Source: CmaxInsight 16 ©CmaxInsight|This report is a licensed product and is not to be photocopied

17. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Drug name: Company name Product Description Xxxxx Research and Development Clinical Studies Clinical Trials Description Intervention (Company) NCT No. Start date 1 ⁰ Phase Status Indication Completion Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Source: CmaxInsight Trial Name: Study Design & Details Phase II Start date Sponsor Population Prior Rx Study Drug/Regimen Comparator/Regimen Endpoints: 1 ⁰ Completion Trial ID Study Design Primary: Secondary: Results Efficacy Safety Interim Results Source Source: CmaxInsight Product Development Activities Designation Deals Patent Technology Funding & financing Key Development Milestone Xxxx 17 ©CmaxInsight|This report is a licensed product and is not to be photocopied

18. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Drug Name General Description Drug Name Generic Name Alias Name Company Product Type Therapy Area Indications Highest Stage of Development for HCM Designation Licensed From Licensing Type Development Partner Institutional Partner Route of Administration Target Mechanism of Action Technology Molecule Type Drug Origin Chemical Name Chemical Formula Molecular Weight CAS Registration No. ATC Classification Source: CmaxInsight 18 ©CmaxInsight|This report is a licensed product and is not to be photocopied

19. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Pre-clinical and Discovery Products Comparative Analysis Figure 6: Pre-clinical and Discovery Stage Products Total Active Products 9 10 8 Number of Products 6 Pre-Clinical Products 2 4 Discovery Products 2 2 0 Stage of Development Source: CmaxInsight Table 4:Pre-clinical and Discovery Stage Products Drug name Company Phase MoA RoA Molecule type Source: CmaxInsight 19 ©CmaxInsight|This report is a licensed product and is not to be photocopied

20. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Drug name: Company name Product Description Xxxxxx Research and Development Pre-clinical Studies Xxxxxx Product Development Activities Designation Deals Patent Technology Funding & financing Key Development Milestone Xxxx 20 ©CmaxInsight|This report is a licensed product and is not to be photocopied

21. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Drug Name General Description Drug Name Generic Name Alias Name Company Product Type Therapy Area Indications Highest Stage of Development for HCM Designation Licensed From Licensing Type Development Partner Institutional Partner Route of Administration Target Mechanism of Action Technology Molecule Type Drug Origin Chemical Name Chemical Formula Molecular Weight CAS Registration No. ATC Classification Source: CmaxInsight 21 ©CmaxInsight|This report is a licensed product and is not to be photocopied

22. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Featured Clinical Evidence for CIAS Product-related evidence Marketed Products Pipeline candidates Non-product related Evidence Table 5: List of featured Clinical Evidence for Cognitive Impairment Associated with Schizophrenia (CIAS) Drug name / Issue Title Source: CmaxInsight Source: CmaxInsight Journal Date Note: This section provides CIAS-Feature Clinical Evidence for last 5 years Inclusion Criteria Rules • • • • • • • • • • Anything about marketed or pipeline drugs Pre-clinical studies of products Real-life experience with marketed therapies Biomarkers Risk factors Patient segmentation Disease progression Diagnosis Treatment Pathogenesis 22 ©CmaxInsight|This report is a licensed product and is not to be photocopied

23. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Universities working on Cognitive Impairment Associated with Schizophrenia (CIAS) Table 6: List of Universities working on Cognitive Impairment Associated With Schizophrenia (CIAS) Drug name / Issue Research Focus & News Source: CmaxInsight Source 23 ©CmaxInsight|This report is a licensed product and is not to be photocopied

24. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Patient Support and Advocacy Resources Table 7: List of Patient Support and Advocacy Resources Association Name Source: CmaxInsight Research Focus & news Country Source 24 ©CmaxInsight|This report is a licensed product and is not to be photocopied

25. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Therapeutic Assessment Assessment by Route of Administration Figure 4:Assessment by Route of Administration 2 1 Oral Intravenous 1 Intranasal Unspecified 12 Source: CmaxInsight Table 8: Assessment by Route of Administration Route of Administration Oral Intravenous Intranasal Unspecified Number of Products 25 ©CmaxInsight|This report is a licensed product and is not to be photocopied

26. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Assessment by Stage and Route of Administration Figure 5:Assessment by Stage and Route of Administration 1 1 Discovery 1 1 1 Pre-clinical Oral 2 1 Phase I Intravenous 3 Phase II Intranasal 4 Unspecified Phase III 1 Filed 0 1 2 3 4 5 No. of Products Source: CmaxInsight Table 9: Assessment by Stage and Route of Administration Route of Administration Stage of Development Filed Phase III Phase II Phase I Pre-clinical Discovery Phase I Pre-clinical Pre- clinical Discovery Number of Products Oral Intravenous Intranasal Unspecified Source: CmaxInsight 26 ©CmaxInsight|This report is a licensed product and is not to be photocopied

27. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Assessment by Molecule Type Figure 6:Assessment by Molecule Type 1 Small Molecule 3 Biologics 2 Peptide Unspecified 2 Source: CmaxInsight Table 10: Assessment by Molecule Type Molecule Type Small Molecule Biologic Peptide Unspecified Number of Products Source: CmaxInsight 27 ©CmaxInsight|This report is a licensed product and is not to be photocopied

28. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Assessment by Stage and Molecule Type Figure 7:Assessment by Stage and Molecule Type 1 1 Discovery 1 1 1 Pre-clinical Small Molecule 2 1 Phase I Biologic 3 Phase II Peptide 4 Unspecified Phase III 1 Filed 0 1 2 3 4 5 No. of Products Source: CmaxInsight Table 11: Assessment by Stage and Molecule Type Molecule Type Stage of Development Filed Phase III Phase II Phase I Pre-clinical Discovery Phase I Pre-clinical Pre- clinical Discovery Number of Products Small Molecule Biologic Peptide Unspecified Source: CmaxInsight 28 ©CmaxInsight|This report is a licensed product and is not to be photocopied

29. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Assessment by Target Figure 8:Assessment by Target 1 Target 1 3 Target 2 2 Target 3 Target 4 2 Source: CmaxInsight Table 12: Assessment by Target Target Target 1 Target2 Target 3 Target 4 Number of Products Source: CmaxInsight 29 ©CmaxInsight|This report is a licensed product and is not to be photocopied

30. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Assessment by Stage and Target Figure 9:Assessment by Stage and Target 1 1 Discovery 1 1 1 Pre-clinical Target 1 2 1 Phase I Target 2 3 Phase II Target 3 4 Target 4 Phase III 1 Filed 0 1 2 3 4 5 No. of Products Source: CmaxInsight Table 13: Assessment by Stage and Target Target Stage of Development Filed Phase III Phase II Phase I Pre-clinical Discovery Phase I Pre-clinical Pre- clinical Discovery Number of Products Target 1 Target2 Target 3 Target 4 30 ©CmaxInsight|This report is a licensed product and is not to be photocopied

31. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Dormant and Discontinued Products Comparative Analysis Figure 10: Dormant and Discontinued Products Total Active Products 9 10 8 Number of Products 6 Dormant Products 2 4 Discontinued Products 2 2 0 Stage of Development Source: CmaxInsight Table 14: Dormant Products Drug Name Company Stage of Dormancy Source: CmaxInsight Table 15: Discontinued Products Drug Name Company Stage of Discontinuation Source: CmaxInsight 31 ©CmaxInsight|This report is a licensed product and is not to be photocopied

32. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Drug name: Company name Product Description Xxxxx Research and Development Clinical Studies Clinical Trials Description Intervention (Company) NCT No. Start date 1 ⁰ Phase Status Indication Completion Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Source: CmaxInsight Product Development Activities Xxxx Reason for Dormancy / Discontinuation Xxxx 32 ©CmaxInsight|This report is a licensed product and is not to be photocopied

33. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Leading Companies Analysis Biogen Inc.: Company Description Biogen Inc. (previously known as Biogen Idec) is an American multinational biotechnology company, specializing in the discovery, development, manufacturing, and delivery of therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases to patients worldwide. It was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp, and has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, Alzheimer’s disease and dementia, multiple sclerosis (MS), and neuroimmunology, movement disorders, neuromuscular disorders, acute neurology, neurocognitive disorders, pain, and ophthalmology. Biogen also manufactures and commercializes biosimilars of advanced biologics. Company marketed products, includes Tecfidera, Avonex, Plegridy, Tysabri, Zinbryta, and Fampyra for MS, Fumaderm for the treatment of severe plaque psoriasis and Spinraza for the treatment of spinal muscular atrophy (SMA). Table 16: Company Profile, 2018 Company Name Entity Industry Headquarter Year Founded Business Segments Biogen Inc Public Biotechnology Cambridge, Massachusetts, United States 1978 Neurodegenerative, hematologic, and autoimmune diseases $ 4.474 Million $ 13,453 Million more than 7,000 employees Michel Vounatsos www.biogen.com Net Revenue Net Income Employees CEO Website Source: CmaxInsight 33 ©CmaxInsight|This report is a licensed product and is not to be photocopied

34. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Company, Total Revenue XXXX Figure 11: Company, Total Revenue Total Revenue (2014-2017) 120 25.00% 100 20.00% Revenue In USD Million 80 15.00% 60 10.00% 40 5.00% 20 0 0.00% 2014 2015 2016 2017 Total Revenue AGR % Source: CmaxInsight Revenue by Business Segments XXXX Figure 12: Company, Revenue by Business Segments REVENUE BY BUSINESS SEGMENT (2018) Other Japan Oceania Middle East Southeast Asia North America Source: CmaxInsight 34 ©CmaxInsight|This report is a licensed product and is not to be photocopied

35. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Geography-Wise Revenue XXXX Figure 13: Company, Geography-Wise Revenue REGION WISE REVENUE (2018) Other Japan Oceania Middle East Southeast Asia North America Source: CmaxInsight 35 ©CmaxInsight|This report is a licensed product and is not to be photocopied

36. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Glossary MCCB: MATRICS Consensus Cognitive Battery UPSA-B: University of California, San Diego Performance Based Skills Assessment-Brief International Version SCoRS: Schizophrenia Cognition Rating Scale PANSS: Positive and Negative Syndrome Scale CGI-S: Clinical Global Impression-Severity (CGI-S) CGI-I: Clinical Global Impression-Improvement (CGI-I) UPSA‑ ‑VIM: University of California, San Diego [UCSD] Performance Based Skills Assessment - Validation of Intermediate Measures) 36 ©CmaxInsight|This report is a licensed product and is not to be photocopied

37. Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence, 2019 Price Report Name Single User License USD 1000 Corporate License USD 2500 Cognitive Impairment Associated with Schizophrenia (CIAS): Pipeline Intelligence- 2019 About CmaxInsight CmaxInsight is a global market research and consulting firm that specialized in providing high- value customized business research, intelligence reports, and databases across pharmaceutical, life science, and healthcare domain. Our aim is to maximize insight with intelligence which assists the clients in decision making and to address new challenges in a fast-paced healthcare environment. We empower healthcare organization at every stage to make the process rapid, better and accurate. We help our clients in bridging the gaps in their business through screening, prioritization, in-depth commercial assessment, independent evaluation of opportunities which facilitating decision-making; identify potential market opportunities, competitor assessments, and business environment assessment. The pharmaceuticals market is in its growth stage and we are uniquely positioned to successfully endeavour the dimensions of the fast growing market by providing cutting-edge market and pipeline information, to our clients. Contact Us If you have any queries about this report or would like further information, please contact us at the below given email address. Email: sales@cmaxinsight.com Disclaimer All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, CmaxInsight. 37 ©CmaxInsight|This report is a licensed product and is not to be photocopied